ARTICLE | Management Tracks
Ceesay joins Coles’ Cerevel as president; plus updates from Replimune, Perceptive, Antiva, Vera, Patient Square, Zymeworks and more
April 22, 2021 12:00 AM UTC
Neuroscience disease company Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) hired Abraham Ceesay as president, a newly created role, starting May 3. Ceesay was CEO at Tiburio Therapeutics Inc.
Oncolytic gene therapy play Replimune Group Inc. (NASDAQ:REPL) hired Sushil Patel as CCO, effective May 3. Patel is a 19-year veteran of Genentech Inc., where he most recently was global oncology franchise head for lung and skin cancers and rare/agnostic tumor types. ...